Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy
Open Access
- 6 October 2025
- journal article
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 15 (6) , 271-281
Abstract
To evaluate treatment perceptions of diroximel fumarate (DRF) for relapsing multiple sclerosis (MS), with contextual data from dimethyl fumarate (DMF) users, based on patient and healthcare provider (HCP) surveys. A prospective web-based survey was conducted among MyMSTeam users aged ≥ 21 years in the United States, who provided information about their MS disease and treatment history. The Spherix HCP survey collected retrospective chart data from HCPs for patients who switched disease-modifying therapies (DMTs). Of 535 MyMSTeam respondents, 77 (14%) received DMF and 46 (9%) received DRF. DRF users reported physical and emotional benefits such as slowed disease progression, decreased relapses, and new symptom prevention, with 70% noting at least one physical benefit and 46% reporting emotional/quality of life benefits. Additionally, 83% found DRF tolerable. HCPs reported prescribing DRF due to good tolerability (58%) and a preference for oral administration (50%). The most common reasons for switching to DRF were lack of efficacy (52%) or poor tolerability (49%) of previous DMTs. A real-world, patient-focused survey on MS treatment suggested DRF was well tolerated and associated with patient-reported physical benefits. HCP-reported reasons for selecting DRF included efficacy and tolerability issues with prior DMT.Keywords
Funding Information
- Biogen
- Biogen
- Biogen
This publication has 21 references indexed in Scilit:
- Lymphocyte dynamics in patients with multiple sclerosis who were treated with dimethyl fumarate and subsequently switched to diroximel fumarateBrain Disorders, 2025
- Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarateMultiple Sclerosis and Related Disorders, 2024
- Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple SclerosisNeurology and Therapy, 2022
- Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future DevelopmentsCNS Drugs, 2022
- Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient InterviewsAdvances in Therapy, 2022
- Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic reviewJournal of Neurology, 2021
- Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and AdherenceNeurology and Therapy, 2021
- Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 StudyCNS Drugs, 2020
- Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 StudyAdvances in Therapy, 2019
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007